WO2002061421A3 - Screening-verfahren zur identifikation von arzneimitteln - Google Patents

Screening-verfahren zur identifikation von arzneimitteln Download PDF

Info

Publication number
WO2002061421A3
WO2002061421A3 PCT/EP2002/001097 EP0201097W WO02061421A3 WO 2002061421 A3 WO2002061421 A3 WO 2002061421A3 EP 0201097 W EP0201097 W EP 0201097W WO 02061421 A3 WO02061421 A3 WO 02061421A3
Authority
WO
WIPO (PCT)
Prior art keywords
fraction
cells
prophylaxis
treatment
treated
Prior art date
Application number
PCT/EP2002/001097
Other languages
English (en)
French (fr)
Other versions
WO2002061421A2 (de
Inventor
Florian Lang
Stefan Huber
Original Assignee
Florian Lang
Stefan Huber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florian Lang, Stefan Huber filed Critical Florian Lang
Priority to AU2002235892A priority Critical patent/AU2002235892A1/en
Publication of WO2002061421A2 publication Critical patent/WO2002061421A2/de
Publication of WO2002061421A3 publication Critical patent/WO2002061421A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G01N2333/445—Plasmodium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Ecology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft ein Screening-Verfahren zur Identifikation von Arzneimitteln zur Behandlung und/oder zur Prophylaxe von Erkrankungen, die durch intrazelluläre Erreger ausgelöst werden, mit den folgenden Schritten: a) Behandlung von nicht-infizierten Zellen mit einem Oxidationsmittel; b) Behandlung mindestens eines Anteils der behandelten Zellen aus Schritt a) mit jeweils mindestens einem potentiellen Arzneimittel, während ein Anteil der behandelten Zellen aus Schritt a) unbehandelt bleibt; c) Quantitative Bestimmung des Hämolyse-Anteils der Anteile an Zellen in isosmotischer Sorbitol-Lösung, die mit mindestens einem potentiellen Arzneimittel in Schritt b) behandelt wurden, im Vergleich zum Hämolyse-Anteil des Anteils an Zellen in isosmotischer Sorbitol-Lösung, der in Schritt b) unbehandelt blieb. Weiterhin betrifft die Erfindung die Verwendung einer antioxidativ wirksamen Substanz, insbesondere Diphenyleneiodonium als eines seiner Salze oder eines Salzes seiner Derivate, zur Herstellung eines Arzneimittels zur Behandlung und/oder zur Prophylaxe von Erkrankungen, die durch intrazelluläre Erreger ausgelöst werden, insbesondere zur Behandlung und/oder zur Prophylaxe von Malaria.
PCT/EP2002/001097 2001-02-01 2002-02-01 Screening-verfahren zur identifikation von arzneimitteln WO2002061421A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002235892A AU2002235892A1 (en) 2001-02-01 2002-02-01 Screening method for identifying medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10104825.4 2001-02-01
DE10104825A DE10104825A1 (de) 2001-02-01 2001-02-01 Screening von Antimalariamitteln

Publications (2)

Publication Number Publication Date
WO2002061421A2 WO2002061421A2 (de) 2002-08-08
WO2002061421A3 true WO2002061421A3 (de) 2003-10-30

Family

ID=7672698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001097 WO2002061421A2 (de) 2001-02-01 2002-02-01 Screening-verfahren zur identifikation von arzneimitteln

Country Status (3)

Country Link
AU (1) AU2002235892A1 (de)
DE (1) DE10104825A1 (de)
WO (1) WO2002061421A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ305247B6 (cs) * 2013-09-20 2015-07-01 Ústav molekulární genetiky AV ČR, v.v.i. Farmaceutický přípravek obsahující difenylenjodonium pro léčení onemocnění vyvolaných parazity čeledi Trypanosomatidae

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018108A1 (fr) * 1993-12-24 1995-07-06 Bioxytech Utilisation de derives 2-mercapto-imidazole substitues en position 4 (ou 5) comme agents antioxydants, leur procede de preparation et leurs applications en pharmacie, cosmetique ou alimentaire
JPH0987196A (ja) * 1995-09-25 1997-03-31 Masatoshi Nakano 寄生虫駆除・駆虫剤
JPH09255589A (ja) * 1996-03-28 1997-09-30 Shiseido Co Ltd ストレス抑制剤
WO1998003178A2 (en) * 1996-07-19 1998-01-29 Smithkline Beecham Plc Pharmaceutical compositions containing p2y purinergic receptor antagonists
US5902831A (en) * 1995-11-27 1999-05-11 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018108A1 (fr) * 1993-12-24 1995-07-06 Bioxytech Utilisation de derives 2-mercapto-imidazole substitues en position 4 (ou 5) comme agents antioxydants, leur procede de preparation et leurs applications en pharmacie, cosmetique ou alimentaire
JPH0987196A (ja) * 1995-09-25 1997-03-31 Masatoshi Nakano 寄生虫駆除・駆虫剤
US5902831A (en) * 1995-11-27 1999-05-11 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
JPH09255589A (ja) * 1996-03-28 1997-09-30 Shiseido Co Ltd ストレス抑制剤
WO1998003178A2 (en) * 1996-07-19 1998-01-29 Smithkline Beecham Plc Pharmaceutical compositions containing p2y purinergic receptor antagonists

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 23, 1997 Derwent World Patents Index; AN 255469 *
DATABASE WPI Week 49, 1997 Derwent World Patents Index; AN 532707 *
LANG F ET AL: "The diversity of volume regulatory mechanisms.", CELLULAR PHYSIOLOGY AND BIOCHEMISTRY: INTERNATIONAL JOURNAL OF EXPERIMENTAL CELLULAR PHYSIOLOGY, BIOCHEMISTRY, AND PHARMACOLOGY. SWITZERLAND 1998, vol. 8, no. 1-2, 1998, pages 1 - 45, XP001106286, ISSN: 1015-8987 *
LEW V L ET AL: "The effects of transport perturbations on the homeostasis of erythrocytes.", NOVARTIS FOUNDATION SYMPOSIUM. ENGLAND 1999, vol. 226, 1999, pages 37 - 50; discussion 50 - 54, XP002215893 *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 07 31 July 1997 (1997-07-31) *
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 01 30 January 1998 (1998-01-30) *

Also Published As

Publication number Publication date
AU2002235892A1 (en) 2002-08-12
DE10104825A1 (de) 2002-08-08
WO2002061421A2 (de) 2002-08-08

Similar Documents

Publication Publication Date Title
NO330888B1 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling av slike, terapeutisk preparatinneholdende slike samt anvendelse av slike for fremstilling av preparat for behandling av sykdom
DE602004005076D1 (de) Coextrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür
WO2006064033A3 (en) Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2005092877A8 (de) Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
NO20064924L (no) Eksperimenteringssikker doseringsform som innbefatter an adsorbent og et skadelig middel
WO2009089011A3 (en) Resveratrol formulations
BR0307291A (pt) Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; método para o tratamento e profilaxia de distúrbios diversos e de obesidade em um humano
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
WO2004056322A3 (en) Antibiotics containing borinic acid complexes and methods of use
WO2005000232A3 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
WO2005107711A3 (en) Method and composition for treating rhinitis
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
CY1110373T1 (el) Συνεργιστικος συνδυασμος που περιλαμβανει ροφλουμιλαστη και εναν αντιχολινεργικο παραγοντα που επιλεγεται απο αλατα τιοτροπιου για την θεραπεια αναπνευστικων ασθενειων
WO2006085932A3 (en) Anti-viral uses of borinic acid complexes
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
WO2004047673A3 (en) Treatment of liver disease with active vitamin d compounds
WO2010067078A3 (en) 3,6-disubstituted xanthylium salts as medicaments
WO2004110151A8 (en) Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
WO2005123651A8 (en) L-2-(α-HYDROXYPENTYL)BENZOATES, THE PREPARATION AND THE USE THEREOF
WO2002061421A3 (de) Screening-verfahren zur identifikation von arzneimitteln

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP